A new Duke University study presents striking evidence of mitochondrial transplant therapy’s superior effectiveness in treating chronic neuropathic pain. The research found an 78% reduction in pain scores following mitochondrial transplantation, compared to only 34% improvement with standard pain medications and just 8% with placebo controls.
This substantial therapeutic advantage is particularly significant given that approximately 25 million Americans suffer from neuropathic pain conditions, many of whom experience inadequate symptom relief with conventional pharmacological approaches. The dramatic performance difference suggests that addressing the underlying cellular energy deficit in damaged nerves may be more effective than masking pain symptoms through traditional medication. The findings underscore a critical gap in current treatment options and position mitochondrial therapy as a potentially transformative intervention for millions of patients with limited alternatives. Read the full article on GMJ Newsroom.
Was this article helpful?
